Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing biological mechanisms and preclinical hypotheses without new human data.
PubMed 37771773 · doi:10.7150/thno.86831
What was done
The authors synthesized existing literature on the role of reactive oxygen species (ROS) in neurodegeneration and reviewed the mechanistic actions of glucagon-like peptide-1 receptor agonists (GLP-1RAs), focusing on Exendin-4, Lixisenatide, and Liraglutide as potential treatments for dementia.
What was found
No quantitative findings or effect sizes are reported in the abstract. The review summarizes that GLP-1RAs reduce ROS generation, improve mitochondrial function, decrease protein aggregation and neuroinflammation, and improve synaptic plasticity and learning/memory, though no single specific pathway for ROS quenching has been established.
Why it matters
Shared metabolic and oxidative stress pathways between diabetes and neurodegenerative diseases provide a mechanistic rationale for repurposing GLP-1 receptor agonists to mitigate cognitive decline.
Limits
This is a narrative review presenting mechanistic and preclinical concepts rather than primary experimental or clinical trial data. The abstract reports no sample sizes, effect estimates, or clinical outcome measures in humans.
Cited by
- supports Inflammation, methylation imbalances, and oxidative stress are key drivers of brain dysfunction and neurodegeneration.